HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M800454-MCP200v1 8/5/1094    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nilsson, A. Articles by Andrén, P. E. Search for Related Content PubMed PubMed Citation Articles by Nilsson, A. Articles by Andrén, P. E. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 8:1094-1104, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease^*,S

Anna Nilsson, Maria Fälth, Xiaoqun Zhang, Kim Kultima, Karl Sköld, Per Svenningsson and Per E. Andrén^,¶

From the Department of Pharmaceutical Biosciences, Medical Mass Spectrometry, Uppsala University, SE-75123 Uppsala, Sweden and Section of Translational Neuropharmacology, Department of Physiology and Pharmacology, Karolinska Institute, SE-17177 Stockholm, Sweden

The principal causative pathology of Parkinson disease is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta projecting to the striatum in the brain. The information regarding the expression of neuropeptides in parkinsonism is very limited. Here we have elucidated striatal neuropeptide mechanisms in experimental parkinsonism using the unilateral 6-hydroxydopamine model to degenerate dopamine neurons. A thoroughly controlled sample preparation technique together with a peptidomics approach and targeted neuropeptide sequence collections enabled sensitive detection, identification, and relative quantitation of a great number of endogenous neuropeptides. Previously not recognized alterations in neuropeptide levels were identified in the unilateral lesioned mice with or without subchronic 3,4-dihydroxy-L-phenylalanine administration, the conventional treatment of Parkinson disease. Several of these peptides originated from the same precursor such as secretogranin-1, somatostatin, prodynorphin, and cholecystokinin. Disease-related biotransformation of precursors into individual peptides was observed in the experimental model of Parkinson disease. Several previously unreported potentially biologically active peptides were also identified from the striatal samples. This study provides further evidence that neuropeptides take part in mediating the central nervous system failure associated with Parkinson disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Kultima, A. Nilsson, B. Scholz, U. L. Rossbach, M. Falth, and P. E. Andren Development and Evaluation of Normalization Methods for Label-free Relative Quantification of Endogenous Peptides Mol. Cell. Proteomics, October 1, 2009; 8(10): 2285 - 2295. [Abstract] [Full Text] [PDF]